Sanegene Bio
- Company typePrivate
- Founded2021
- HeadquartersWoburn, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
Sanegene Bio firmographics
Firmographics- Name
- Sanegene Bio
- Legal name
- SanegeneBio
- Website
- https://sanegenebio.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Sanegene Bio industry classification
Industry- Product category
- RNAi Therapeutics / Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
- akta.pro secondary industries
- RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE), RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF)
Keywords
Where Sanegene Bio is headquartered
LocationHeadquarters
- HQ city
- Woburn
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Sanegene Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Licensing and Milestone Payments: Upfront payments, development and commercialization milestone payments, and tiered royalties on future product sales from licensing agreements with pharmaceutical partners.
- Strategic Partnerships and Co-development: Revenue from co-development arrangements including cost-sharing, milestone payments, and potential royalty streams from partner-funded clinical development programs.
- Equity Financing: Series B financing of over $110 million raised from institutional investors, strategic investors, and existing shareholders to fund R&D operations and clinical development.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Sanegene Bio product offering
Product offeringCore offering
SanegeneBio develops RNAi-based therapeutics that silence disease-causing genes, with a clinical pipeline targeting obesity and metabolic disorders, complement-mediated autoimmune diseases (IgA nephropathy, C3 glomerulopathy, PNH, aHUS), and cardiovascular diseases (hypertension, dyslipidemia, cardiomyopathy). The company's candidates leverage the proprietary LEAD™ delivery platform for tissue-selective gene silencing in liver and extrahepatic tissues, including adipocytes, skeletal muscle, and immune cells, with potential for bi-annual subcutaneous dosing. Revenue is generated through out-licensing and co-development partnerships with Eli Lilly, Genentech/Roche, and Innovent Biologics.
Product overview
SanegeneBio is a clinical-stage biotech developing a diversified pipeline of RNAi-based therapeutics for metabolic/obesity, cardiovascular, and autoimmune diseases. The portfolio is powered by the proprietary LEAD™ (Ligand and Enhancer Assisted Delivery) platform enabling tissue-selective delivery to liver, adipose, muscle, and immune cells. Core clinical programs include SGB-7342 (INHBE, obesity), SGB-9768 (C3, complement-mediated diseases), and SGB-3908 (AGT, hypertension, partnered with Innovent). The company has multiple preclinical and clinical-stage candidates spanning obesity, dyslipidemia, cardiomyopathy, and coagulopathies.
Differentiator
Problem solved
Functional benefit
Products and services
- LEAD™ (Ligand and Enhancer Assisted Delivery) Platform Proprietary tissue-selective RNAi delivery technology that enables targeted gene silencing in liver, adipose tissue, skeletal muscle, and immune cells through novel receptor-mediated internalization mechanisms. Supports bi-annual subcutaneous dosing potential with a GalNAc-like safety profile, and is the core enabling platform for SanegeneBio's pipeline of RNAi therapeutic candidates.
- SGB-7342 GalNAc-conjugated siRNA therapeutic targeting INHBE (Inhibin Beta E) mRNA in hepatocytes for the treatment of obesity. Designed to reduce circulating Activin E levels and improve metabolic abnormalities while preserving lean muscle mass, addressing limitations of GLP-1 therapies.
- SGB-9768 GalNAc-conjugated siRNA therapeutic targeting complement C3 mRNA in hepatocytes for complement-mediated kidney and hematologic diseases including IgA Nephropathy (IgAN), C3 Glomerulopathy (C3G), IC-MPGN, Paroxysmal Nocturnal Hemoglobinuria (PNH), and atypical Hemolytic Uremic Syndrome (aHUS). Demonstrated best-in-class potential with 96.3% maximum reduction in serum C3 levels and 100% inhibition of alternative pathway activity.
- SGB-3908 GalNAc-conjugated siRNA therapeutic targeting angiotensinogen (AGT) mRNA for the treatment of hypertension, jointly developed with Innovent Biologics (Innovent designation: IBI3016). Demonstrated sustained AGT mRNA reduction with potential for biannual dosing.
- SGB-3383 siRNA therapeutic targeting complement factor B (CFB) in the liver for complement-mediated diseases including atypical Hemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH). SanegeneBio retains global commercial rights.
- SGB-BS01 siRNA therapeutic targeting PCSK9 and ANGPTL3 in the liver for dyslipidemia. SanegeneBio retains global commercial rights.
- SGB-BS02 siRNA therapeutic targeting PCSK9 and LPA in the liver for dyslipidemia. SanegeneBio retains global commercial rights.
- SGB-CV01 siRNA therapeutic targeting an undisclosed gene in the heart for cardiomyopathy. SanegeneBio retains global commercial rights.
- SGB-OB03 siRNA therapeutic targeting an undisclosed gene in adipose tissue for obesity. SanegeneBio retains global commercial rights.
- SGB-OB04 siRNA therapeutic targeting ACVR2 in skeletal muscle for obesity and other indications. SanegeneBio retains global commercial rights.
- SGB-3252 siRNA therapeutic targeting PLG in the liver for coagulopathies including Hereditary Hemorrhagic Telangiectasia (HHT) and Heavy Menstrual Bleeding (HMB). SanegeneBio retains global commercial rights.
- SGB-IM03 siRNA therapeutic targeting MST1 in the liver for COPD and other immune conditions. SanegeneBio retains global commercial rights.
Quantifiable outcome
- SGB-9768 achieved 96.3% maximum reduction in serum C3 levels and 100% inhibition of alternative pathway activity maintained through Week 24 in Phase 1
- +2 more outcomes
Companies that use Sanegene Bio
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Sanegene Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Sanegene Bio partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered major, core and supporting.
- Genentech (Roche Group)majorGlobal licensing agreement for one of SanegeneBio's RNAi programs using LEAD™ platform targeting metabolic and autoimmune conditions. SanegeneBio receives $200 million upfront and eligible for up to $1.5 billion in development and commercialization milestones plus tiered royalties. Genentech leads all future clinical development and worldwide commercialization.
- Innovent BiologicscoreJoint development partnership for SGB-3908 (IBI3016), an siRNA targeting angiotensinogen for hypertension treatment. Phase 1 data presented at AHA 2025. Innovent and SanegeneBio collaborating on clinical development with Innovent conducting Phase 2 and 3 trials in Asia while SanegeneBio handles Phase 3 globally.
- Eli Lilly and CompanymajorGlobal research and licensing collaboration for RNAi therapeutics targeting metabolic diseases using SanegeneBio's LEAD™ platform. SanegeneBio responsible for discovery and identification of optimized LEAD™-based RNAi molecules; Lilly handles IND-enabling studies, clinical development and commercialization. Deal includes upfront payment, equity investment, near-term milestones, and potential milestones up to $1.2 billion plus tiered royalties.
- Orbit Discovery LimitedsupportingPartnership to identify tissue-specific delivery mechanisms for RNA therapeutics through hit identification and cell-based internalization studies, expanding SanegeneBio's delivery capabilities.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Sanegene Bio competitors and assessment
Company assessmentDirect peers
- Wave Life Sciences: Wave is a clinical-stage genetic medicines company developing stereopure oligonucleotide therapeutics including siRNA and other modalities. Comparable to Sanegene in stage and oligonucleotide chemistry focus, with overlapping targets in metabolic and rare diseases via partnerships with GSK and Takeda.
- Rona Therapeutics: Rona Therapeutics is a clinical-stage Chinese RNAi company developing siRNA therapeutics for metabolic and rare diseases, founded by ex-Sanofi and ex-Alnylam executives. Closely comparable to Sanegene in target indications (obesity, complement), modality, and stage, and competes in the same China-led RNAi development ecosystem.
- Arrowhead Pharmaceuticals: Arrowhead is a clinical-stage RNAi therapeutics company developing multiple TRiM-enabled siRNA programs across metabolic, cardiovascular, and rare disease indications. Closely comparable to Sanegene in stage, modality (GalNAc-conjugated siRNA), and indication focus, with a similar partnership-driven business model (Amgen, Takeda, GSK, Sanofi).
- Silence Therapeutics: Silence Therapeutics is a clinical-stage RNAi company developing GalNAc-conjugated siRNA therapies for cardiovascular and hematologic diseases. Its SLN360 (Lp(a)) and SLN124 (TMPRSS6) programs overlap directly with Sanegene's cardiovascular and complement pipelines, making it a closely matched direct peer in technology and stage.
Others
- Innovent Biologics: Innovent is a leading Chinese biopharmaceutical company that is both a strategic partner to Sanegene (co-developing SGB-3908 for hypertension in Asia) and an adjacent comparator as a China-based clinical-stage biologics developer. While not an RNAi competitor, it is a relevant ecosystem participant and commercialization partner.
Regional players
- Sirnaomics: Sirnaomics is a clinical-stage RNAi therapeutics company headquartered in Maryland with R&D operations in China, developing siRNA candidates for oncology and fibrosis. Highly comparable to Sanegene in cross-border US-China biotech structure, oligonucleotide modality, and clinical-stage profile, making it a regional/structural peer.
Broad incumbents
- Arrowhead Pharma subsidiary (was) + Novartis siRNA efforts: Novartis, through its partnership with Alnylam on Leqvio (inclisiran, an siRNA targeting PCSK9) and its own oligonucleotide programs, is a broad incumbent in the siRNA cardiovascular space. Directly comparable to Sanegene's PCSK9/ANGPTL3 dyslipidemia programs and represents the type of large-pharma commercialization infrastructure Sanegene aspires to access.
- Alnylam Pharmaceuticals: Alnylam is the leading commercial-stage RNAi therapeutics company with multiple FDA-approved siRNA drugs (Onpattro, Givlaari, Oxlumo, Amvuttra, Leqvio via partnership). It is the dominant player in GalNAc-conjugated liver RNAi and serves as both a direct technology comparable and the primary competitive benchmark for Sanegene's siRNA pipeline.
- Dicerna Pharmaceuticals (Novo Nordisk): Dicerna was a clinical-stage RNAi company acquired by Novo Nordisk in 2021 for $3.3B; its GalXC RNAi platform is now integral to Novo's oligonucleotide pipeline in cardiometabolic and rare diseases. As a former pure-play RNAi competitor now embedded in a major pharma, it represents the strategic exit template most relevant to Sanegene.
Emerging players
- Viridian Therapeutics: Viridian is a clinical-stage biopharmaceutical company developing siRNA and antibody therapies for autoimmune and rare diseases. While its current lead programs are antibody-based (anti-IGF-1R, anti-FcRn), its emerging RNAi interest and metabolic disease focus make it a partially overlapping emerging peer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key highlights7 records
Customer concentration
Sanegene Bio social profiles
Digital presenceSanegene Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sanegene Bio leadership team
Management profileNumber of profiles
Profiles9 records
Sanegene Bio funding detail
Funding detailFunding overview
Funding rounds6 records
Investors24 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sanegene Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sanegene Bio
What does Sanegene Bio do?
SanegeneBio develops RNAi-based therapeutics that silence disease-causing genes, with a clinical pipeline targeting obesity and metabolic disorders, complement-mediated autoimmune diseases (IgA nephropathy, C3 glomerulopathy, PNH, aHUS), and cardiovascular diseases (hypertension, dyslipidemia, cardiomyopathy). The company's candidates leverage the proprietary LEAD™ delivery platform for tissue-selective gene silencing in liver and extrahepatic tissues, including adipocytes, skeletal muscle, and immune cells, with potential for bi-annual subcutaneous dosing. Revenue is generated through out-licensing and co-development partnerships with Eli Lilly, Genentech/Roche, and Innovent Biologics.
Is Sanegene Bio a public or private company?
Sanegene Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Sanegene Bio founded?
Sanegene Bio was founded in 2021. It employs 51 to 100 people.
Where is Sanegene Bio based?
Sanegene Bio is headquartered in Woburn, United States, in the North America region.
How does Sanegene Bio make money?
Three revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are strategic Partnerships and Co-development and equity Financing.
Who are Sanegene Bio's main competitors?
Direct peers on record are Wave Life Sciences, Rona Therapeutics, Arrowhead Pharmaceuticals and Silence Therapeutics. Innovent Biologics is listed as an others. Sirnaomics is listed as a regional player. Broad incumbents are Arrowhead Pharma subsidiary (was) + Novartis siRNA efforts, Alnylam Pharmaceuticals and Dicerna Pharmaceuticals (Novo Nordisk). Viridian Therapeutics is listed as an emerging player.
Does Sanegene Bio have an API?
No public API is recorded for Sanegene Bio.
What industry is Sanegene Bio in?
Sanegene Bio's product category is RNAi Therapeutics / Biopharmaceuticals. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 325414 and its SIC code is 2836.